These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 35442467)
1. Topical tacrolimus during systemic therapy for severe atopic dermatitis in the clinical practice. Ferrucci SM; Angileri L; Marzano AV; Berti E; Tavecchio S Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2518-2523. PubMed ID: 35442467 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dupilumab plus topical tacrolimus for atopic dermatitis in 6- to 12-year-old patients. Gao SS; Chen M; Wang R; Chen JG Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9830-9837. PubMed ID: 37916349 [TBL] [Abstract][Full Text] [Related]
3. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24. Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice. Matsutani M; Imai Y; Inoue Y; Nakatani-Kusakabe M; Natsuaki M; Yamanishi K; Kanazawa N J Dermatol; 2021 Oct; 48(10):1564-1568. PubMed ID: 34155694 [TBL] [Abstract][Full Text] [Related]
5. Exploring the Relationship Between Dermatology Life Quality Index, Eczema Area and Severity Index, and Sleep Numerical Rating Scale and Pruritus Numerical Rating Scale in Patients with Atopic Dermatitis Treated with Dupilumab. Russo F; Cioppa V; Cartocci A; De Piano E; Taddeucci P; Lazzeri L; Santi F; Rubegni P Dermatitis; 2023; 34(5):440-444. PubMed ID: 36917539 [No Abstract] [Full Text] [Related]
6. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study. Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611 [TBL] [Abstract][Full Text] [Related]
8. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. Won CH; Seo PG; Park YM; Yang JM; Lee KH; Sung KJ; Park CW; Kim DW; Chang HS; Won YH; Kim KH J Dermatolog Treat; 2004 Jan; 15(1):30-4. PubMed ID: 14754647 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis. Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874 [TBL] [Abstract][Full Text] [Related]
10. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. Tsianakas A; Luger TA; Radin A Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523 [TBL] [Abstract][Full Text] [Related]
11. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis. Milanesi N; Gola M; Cartocci A; Tronconi G; Bruzziches F; Flori ML; Rubegni P; Russo F Ital J Dermatol Venerol; 2022 Apr; 157(2):142-145. PubMed ID: 34282867 [TBL] [Abstract][Full Text] [Related]
12. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350 [TBL] [Abstract][Full Text] [Related]
13. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791 [No Abstract] [Full Text] [Related]
14. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study. Ureña-Paniego C; Montero-Vílchez T; Sanabria-de-la-Torre R; Soto-Moreno A; Molina-Leyva A; Arias-Santiago S Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767285 [TBL] [Abstract][Full Text] [Related]
15. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A Actas Dermosifiliogr; 2024 Feb; 115(2):T150-T158. PubMed ID: 38048951 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A Actas Dermosifiliogr; 2024 Feb; 115(2):150-158. PubMed ID: 37858860 [TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK. O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083 [TBL] [Abstract][Full Text] [Related]
19. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972 [TBL] [Abstract][Full Text] [Related]
20. Dupilumab in Elderly Patients With Severe Atopic Dermatitis. Russo F; Milanesi N; Cartocci A; Bruzziches F; Tronconi G; Lazzeri L; D'erme AM; Bagnoni G; Gola M; Cinotti E; Rubegni P; Flori ML Dermatitis; 2021 Oct; 32(1S):S24-S27. PubMed ID: 33332865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]